ACLARION, INC. Proceeds from Lines of Credit
ACLARION, INC. (ACON) reported Proceeds from Lines of Credit of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2026-03-18
- ACLARION, INC. proceeds from lines of credit for the quarter ending 2025-12-31 was $0.00.
- ACLARION, INC. proceeds from lines of credit for the quarter ending 2025-09-30 was $0.00.
- ACLARION, INC. proceeds from lines of credit for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- ACLARION, INC. proceeds from lines of credit for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- ACLARION, INC. proceeds from lines of credit for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ACLARION, INC. proceeds from lines of credit for fiscal 2024 was $1.75M, a 19.90% increase from fiscal 2023.
- ACLARION, INC. proceeds from lines of credit for fiscal 2023 was $1.46M.
- ACLARION, INC. proceeds from lines of credit for fiscal 2022 was $0.00.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $0.00 derived: sum of 2 quarters · filed 2026-03-18 | $0.00 derived: sum of 3 quarters · filed 2026-03-18 | $0.00 10-K · filed 2026-03-18 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-18 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | $0.00 derived: sum of 3 quarters · filed 2026-03-18 | $0.00 derived: sum of 4 quarters · filed 2026-03-18 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-03-18 | $0.00 derived: sum of 3 quarters · filed 2026-03-18 | $304.50K derived: sum of 4 quarters · filed 2026-03-18 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $0.00 derived: sum of 2 quarters · filed 2026-03-18 | $304.50K derived: sum of 3 quarters · filed 2026-03-18 | $1.75M 10-K · filed 2026-03-18 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $304.50K derived: sum of 2 quarters · filed 2025-11-12 | $1.75M 10-Q · filed 2025-11-12 | $3.22M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $304.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $1.75M 10-Q · filed 2025-08-14 | $3.22M derived: sum of 3 quarters · filed 2025-08-14 | $3.22M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.45M 10-Q · filed 2025-05-15 | $2.91M derived: sum of 2 quarters · filed 2025-05-15 | $2.91M derived: sum of 3 quarters · filed 2025-05-15 | $2.91M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-09 | $1.46M derived: sum of 2 quarters · filed 2025-04-09 | $1.46M derived: sum of 3 quarters · filed 2025-04-09 | $1.46M 10-K · filed 2025-04-09 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |